Surf Wiki
Save to docs
general/medical-treatments

From Surf Wiki (app.surf) — the open knowledge base

Celacade

Celacade was a non-drug, device-based treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian-based biotherapeutics company Vasogen, Inc. for chronic heart failure and peripheral artery disease. Blood was piped through the device, where it was exposed to heat, ultraviolet light, and ozone, in the hope that this oxidative stress would trigger an anti-inflammatory immunomodulation response.

Despite some promising early results and one positive result in subgroup analysis, the technique usually did not produce the hoped-for clinically significant results.

Research history

At the World Congress of Cardiology in September 2006 the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) a phase III randomized, double-blind, placebo-controlled clinical trial involving some 2408 patients in 7 countries with left ventricular ejection fraction of 30% or less, reported that only one subgroup – patients with a previous cardiovascular event – benefited from the treatment. These people were 39% less likely to die or be hospitalized due to a heart attack or stroke and tended to have improved quality of life.

Marketing approval

Vasogen in collaboration with Grupo Ferrer Internacional has regulatory approval to market Celacade as a medical device for the treatment of chronic heart failure in the European Union and Latin America.

References

References

  1. Visioli F. (September 2001). "VasoCare. Vasogen". Curr Opin Investig Drugs.
  2. (2002). "Immune modulation therapy-peripheral vascular disease--Vasogen (VasoCare)". Drugs in R&D.
  3. Kumar, Soumitra. (2018-03-31). "The Protocol Book for Intensive Care". JP Medical Ltd.
  4. (1997). "Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations". J. Biol. Regul. Homeost. Agents.
  5. (2013-07-29). "Biomarkers in Cardiovascular Diseases". CRC Press.
  6. (April 2007). "A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design". Can J Cardiol.
  7. link. "Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade in the European Union". Vasogen Inc. April 18, 2007
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

medical-treatments
Want to explore this topic further?

Ask Mako anything about Celacade — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report